The estimated Net Worth of Capital Investments Ltd.Rid... is at least $19.7 Million dollars as of 14 January 2008. Capital Rid owns over 700,000 units of Acorda Therapeutics Inc stock worth over $1,734,983 and over the last 17 years Capital sold ACOR stock worth over $17,976,000.
Capital has made over 1 trades of the Acorda Therapeutics Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently Capital sold 700,000 units of ACOR stock worth $17,976,000 on 14 January 2008.
The largest trade Capital's ever made was selling 700,000 units of Acorda Therapeutics Inc stock on 14 January 2008 worth over $17,976,000. On average, Capital trades about 700,000 units every 0 days since 2008. As of 14 January 2008 Capital still owns at least 2,628,762 units of Acorda Therapeutics Inc stock.
You can see the complete history of Capital Rid stock trades at the bottom of the page.
Over the last 19 years, insiders at Acorda Therapeutics Inc have traded over $155,173,492 worth of Acorda Therapeutics Inc stock and bought 1,139,691 units worth $17,085,546 . The most active insiders traders include Capital Management Lp Scopi..., Ian F Smith und Ron Cohen. On average, Acorda Therapeutics Inc executives and independent directors trade stock every 19 days with the average trade being worth of $19,752. The most recent stock trade was executed by Ron Cohen on 16 March 2023, trading 20,156 units of ACOR stock currently worth $12,497.
acorda therapeutics is a publicly traded (nasdaq: acor) biotechnology company whose mission is to develop therapies that restore neurological function and improve the lives of people with neurological disorders. we started our company in 1995 as a network of scientists, physicians and business people with a common belief that sharing ideas and information could lead to innovative medical advances for people with neurological disorders. we have since evolved into a commercial-stage biotechnology company, successfully developing and commercializing important therapies that advance the care of people affected by neurological conditions. we achieve our goals by: • investing in research and development • collaborating closely with the patient, medical and scientific communities • retaining employees with compassion and commitment acorda has been voted one of the best companies to work for in new york for the past five years in a row, as a result of our dynamic environment, strong corporate
Acorda Therapeutics Inc executives and other stock owners filed with the SEC include: